Peptides and preparations compared
A change of name can be harmless. A change of ingredient changes the experiment. Lookalikes need room between them.
The identity comparison
| Name encountered | Preparation behind the finding |
|---|---|
| BPC-157 | Synthetic gastric-derived peptide; the rat tendon experiment tested BPC 157. |
| GHK-Cu | GHK bound to copper; the human-skin experiment reports copper permeation and retention. |
| GHK hair research | GHK combined with 5-aminolevulinic acid; the randomised hair trial tested the combination. |
| TB-500 | Ac-LKKTETQ fragment; the rat stroke result and human Phase 1 safety data concern full-length thymosin β4. |
I see three different attribution problems here. Copper can disappear from an account of GHK-Cu, a partner ingredient can disappear from a combination trial, and a whole protein can disappear into a fragment's name. Each omission makes a cleaner story at the cost of identifying what was tested.
Human observations
BPC-157 has a two-person intravenous safety pilot. A 2025 review counted three small human pilots in total and described the lack of rigorous large-scale trials. The animal repair literature is much broader.
The human GHK-related observations are principally topical: small skin studies summarised in reviews, the combination trial in 45 men and human skin examined outside the body. That last experiment used human material, with no clinical treatment outcome in living participants.
Full-length thymosin β4 has the 40-volunteer intravenous safety study. For the TB-500 fragment, completed controlled human trials are absent. The parent's tolerability leaves the fragment's efficacy undecided.
From a repair result to a nerve claim
A rat tendon regained strength and organisation under BPC 157. Skin studies recorded collagen and appearance changes. A rat stroke study measured neurological function under full-length thymosin β4. Those endpoints describe different biological tasks.
The BPC-157 brain-gut review describes rodent neurotransmitter systems and signalling. The thymosin β4 stroke experiment concerns a central nervous system injury. None of the sources listed here reports a peripheral nerve regenerating in a person under these compounds.
For me, that boundary resolves the comparison more honestly than an overall winner could. A name can assemble a literature; it cannot make the endpoints interchangeable.
Status follows the substance and route
BPC-157 has no FDA-approved medicinal product and WADA prohibits it at all times; FDA lists its withdrawn compounding nomination with safety concerns. A withdrawn nomination establishes neither approval nor permission for 503A compounding.
GHK-Cu is familiar as topical Copper Tripeptide-1, a legal cosmetic ingredient in the US, EU and UK. Injectable and oral systemic use is unapproved. Its absence from the 2024–2025 WADA lists has to be read alongside the S0 catch-all category for non-approved pharmacological substances.
TB-500 has no approved therapeutic indication and is prohibited in sport under peptide and growth-factor categories. Research and veterinary contexts explain its circulation; they do not establish a human treatment.